BioCentury
ARTICLE | Company News

Neopharm, Prima BioMed deal

March 3, 2014 8:00 AM UTC

Prima granted Neopharm an exclusive license to market Prima's CVac in Israel and the Palestinian Authority. In November, the companies entered into a binding term sheet for the deal. Prima will receive a "small" upfront payment and is eligible for development milestones. Neopharm will reimburse Prima for commercial manufacturing costs of CVac, and the partners will split net profits from CVac sales in the territories (see BioCentury, Nov. 18, 2013). ...